Journal ArticleDOI
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.
Bernard Escudier,Robert J. Motzer,Padmanee Sharma,John Wagstaff,Elizabeth R. Plimack,Hans J. Hammers,Frede Donskov,Howard Gurney,Jeffrey A. Sosman,Pawel Zalewski,Ulrika Harmenberg,David F. McDermott,Toni K. Choueiri,Martin Eduardo Richardet,Yoshihiko Tomita,Alain Ravaud,Justin Doan,Huanyu Zhao,Helene Hardy,Saby George +19 more
TLDR
A subset of patients with advanced renal cell carcinoma and disease progression may continue to benefit from nivolumab treatment beyond progression as evidenced by tumor reduction postprogression and an acceptable safety profile.About:
This article is published in European Urology.The article was published on 2017-09-01. It has received 187 citations till now. The article focuses on the topics: Nivolumab & Response Evaluation Criteria in Solid Tumors.read more
Citations
More filters
Summary of product characteristics
Helen Andrew,Gemma Gossedge,Julie Croft,Neil Corrigan,Julia Brown,Nicholas West,Philip Quirke,Damian Tolan,Ronan A. Cahill,David Jayne +9 more
TL;DR: Trimetazidine is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies.
Journal ArticleDOI
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.
TL;DR: Predictive biomarkers, mechanisms of resistance, hyperprogressors, treatment duration and treatment beyond progression, immune-related toxicities, and clinical trial design are key concepts in need of further consideration to optimize the anticancer potential of this class of immunotherapy.
Journal ArticleDOI
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Roberto Ferrara,Laura Mezquita,M. Texier,J. Lahmar,Clarisse Audigier-Valette,Laurent Tessonnier,Julien Mazieres,Gérard Zalcman,Solenn Brosseau,Sylvestre Le Moulec,L. Leroy,Boris Duchemann,Corentin Lefebvre,Remi Veillon,Virginie Westeel,Serge Koscielny,Stéphane Champiat,Charles Ferté,David Planchard,Jordi Remon,Marie Eve Boucher,Anas Gazzah,Julien Adam,Emilio Bria,Giampaolo Tortora,Jean-Charles Soria,Benjamin Besse,Benjamin Besse,Caroline Caramella +28 more
TL;DR: It is suggested that HPD is more common with PD-1/PD-L1 inhibitors compared with chemotherapy in pretreated patients with NSCLC and is also associated with high metastatic burden and poor prognosis in patients treated with PD.
Journal ArticleDOI
Novel patterns of response under immunotherapy.
Edith Borcoman,Yada Kanjanapan,Stéphane Champiat,Shumei Kato,Vincent Servois,Razelle Kurzrock,Sanjay Goel,Philippe L. Bedard,C. Le Tourneau,C. Le Tourneau +9 more
TL;DR: Initially reported in advanced melanoma patients, pseudoprogression occurs when tumor index lesions regress after initial progression, supporting the concept of treating some patients beyond progression, and the classic RECIST remains a reasonable and meaningful method to assess response to immunotherapy in the clinic.
Journal ArticleDOI
Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy
TL;DR: This article provides a comprehensive review of the early and late phase trials that led to the regulatory approval of all five PD1‐ PDL‐1 inhibitors in the corresponding cancer types and presents available data on the combinations of PD1 • PDL •1 inhibitors with other therapies, the toxicity profile of the PD1• PDL•1 inhibitors and ongoing trials testing the efficacy of these agents in cancer types beyond those that have been addressed already.
References
More filters
Journal ArticleDOI
Updated efficacy and > 1-y follow up from IMvigor210: Atezolizumab (atezo) in platinum (plat) treated locally advanced/metastatic urothelial carcinoma (mUC).
Robert Dreicer,Jean H. Hoffman-Censits,Thomas W. Flaig,Enrique Grande,Ani Sarkis Balmanoukian,Gunhild von Amsberg,Christine Theodore,Simon Chowdhury,Sergio Bracarda,Jessica M. Clement,Evan Y. Yu,Arash Rezazadeh Kalebasty,Guenter Niegisch,Stéphane Culine,Michael S. Gordon,Na Cui,Sanjeev Mariathasan,Fatema A. Legrand,Oyewale O. Abidoye,Daniel P. Petrylak +19 more
TL;DR: Atezo (MPDL3280A) has been found to be a high-efficacy chemotherapy agent in mUC patients treated with chemo who have low ORRs and short OS.
Journal ArticleDOI
FDA analysis of treatment beyond disease progression disease (PD) in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab vs. everolimus.
Chana Weinstock,Virginia Ellen Maher,Lijun Zhang,James Xu,Shenghui Tang,Rajeshwari Sridhara,Amna Ibrahim,Geoffrey Kim,Richard Pazdur +8 more
TL;DR: This data indicates that conventional measurement of disease progression by RECIST v1.1 criteria may not fully capture patient benefit from PD-1 and PD-L1 inhibitors.
Journal ArticleDOI
Effectiveness of bevacizumab exposure beyond disease progression in patients with non-small-cell lung cancer: analyses of the ARIES observational cohort study.
Larry Leon,Michael P. Kosty,Mohammad Jahanzeb,David R. Spigel,Antoinette J. Wozniak,Julie R. Brahmer,S. Fish,E. Dawn Flick,Sebastien Hazard,Thomas J. Lynch +9 more
TL;DR: Bevacizumab used in combination with first‐line chemotherapy confers an overall survival benefit for patients with non‐squamous non‐small‐cell lung cancer (NSCLC) and this analysis from the ARIES observational cohort study was initiated to evaluate the effect of bevacIZumab use beyond disease progression (BBP) on clinical outcomes.
Related Papers (5)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Bernard Escudier,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Toni K. Choueiri,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Yoshihiko Tomita,Fabio A.B. Schutz,Christian Kollmannsberger,James Larkin,Alain Ravaud,Jason S. Simon,Li-an Xu,Ian M. Waxman,Padmanee Sharma +26 more
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Hossein Borghaei,Luis Paz-Ares,Leora Horn,D. R. Spigel,M. Steins,Neal Ready,L.Q. Chow,Everett E. Vokes,Enriqueta Felip,Esther Holgado,F. Barlesi,M. Kohlhufl,Oscar Arrieta,Marco Angelo Burgio,J. Fayette,H. Lena,Elena Poddubskaya,David E. Gerber,Scott N. Gettinger,Charles M. Rudin,Naiyer A. Rizvi,L. Crina,G. R. Blumenschein,Scott J. Antonia,C. Dorange,C. T. Harbison,F. Graf Finckenstein,Julie R. Brahmer +27 more
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Nizar M. Tannir,David F. McDermott,Osvaldo Arén Frontera,Bohuslav Melichar,Toni K. Choueiri,Elizabeth R. Plimack,Philippe Barthélémy,Camillo Porta,Saby George,Thomas Powles,Frede Donskov,V. Neiman,V. Neiman,Christian Kollmannsberger,Pamela Salman,Howard Gurney,Robert E. Hawkins,Alain Ravaud,Marc-Oliver Grimm,Sergio Bracarda,Carlos H. Barrios,Yoshihiko Tomita,Daniel Castellano,Brian I. Rini,Allen C. Chen,Sabeen Mekan,M. Brent McHenry,Megan Wind-Rotolo,Justin Doan,Padmanee Sharma,Hans J. Hammers,Hans J. Hammers,Bernard Escudier +33 more